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Stress, Endogenous Opioid Peptides, and 
the Reinforcement Value of Nicotine 
Several recent reviews of the neurobiology of drug abuse implicate common 
biological mechanisms as serving a prominent role in drug reinforcement and 
addiction. For example, Wise and Bozarth (1987) offer the theory that positive 
reinforcement and psychomotor stimulation rely on a common biological 
mechanism. According to this theory, reinforcing and stimulating properties of a 
given drug employ common dopaminergic pathways that project from the 
midbrain through the medial forebrain bundle (MFB) to the cortical regions. This 
theory is founded on numerous studies that have established a dopaminergic 
link among many drugs of abuse, such as amphetamines, cocaine, opiates, 
alcohol, and nicotine. lzenwasser and Kornetsky (1992) also identify 
dopaminergic activity as the main contributor to the neurochemical basis of drug 
reinforcement. Like Wise and Bozarth (1987), lzenwasser and Kornetsky 
implicate the mesolimbic dopaminergic pathway which begins in the ventral 
tegmental area r,JTA) and projects to several frontal areas including the nucleus 
accumbens (NA). Most recently, Robinson and Berridge (1993) have described 
the importance of the mesolimbic pathways. According to Robinson and 
Berridge (1993), repeated activation of these pathways powerfully enhances the 
attribution of incentive salience to drugs and drug related cues, which leads to 
pathological craving. 
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Endogenous Opioid Peptides, Stress, and the Reinforcement Pathways 
In addition to discussing the dopaminergic reinforcement pathways, 
lzenwasser and Kornetsky (1992) emphasize the involvement of endogenous 
opioid peptides (EOPs) as a biological correlate of the dopaminergic activity. 
Several studies using an intracranial self-stimulation (ICSS) paradigm have 
shown that the administration of drugs that activate the dopaminergic pathways 
often results in an increase in the ICSS rate as well as a decrease in the 
threshold at which the ICSS is reinforcing. EOPs are suspected of playing an 
important role in drug reinforcement because of the high number of enkephalins 
and opioid binding sites along the reinforcement pathways and because opioid 
antagonists, such as naloxone, often prevent an increase in the ICSS rate and 
prevent a decrease of the reinforcement threshold. 
Stress is often believed to be associated with the initiation and maintenance 
of drug abuse. A sizable literature has associated stress and negative affect with 
the initiation and maintenance of drug abuse. For example, Fulmer & Lapidus 
(1980) found that negative emotional states are involved in the maintenance of 
use and to a lesser degree in the initiation of use. Some have attributed this 
association to the ability of drugs, such as alcohol and nicotine, to reduce 
negative affect. However, studies that directly test this model have provided 
inconsistent findings. With alcohol for example, some studies have supported a 
reduction of negative affect (Josephs & Steele, 1990; Levenson, Sher, 
Grossman, Newman, & Newlin, 1980) and other studies refute this idea 
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(Rohsenow, 1982; Sayette & Wilson, 1991 ). These inconsistencies may be a 
result of different methodology and different definitions of negative emotional 
states (e.g., as anxiety; tension, hostility, anger, or depression). Alternatively, 
the tension reduction model may not be a sufficient description of the 
relationship between stress and drug abuse. Other researchers believe that 
stress results in individual mood states which mediate the relationship between 
stress and drug abuse (Hussong & Chassin, 1994). Negative mood states have 
also been conceptualized as internal cues for drug administration (Childress et. 
al., 1994; Powell et. al., 1990). 
In terms of the pharmacology of stress, it has been widely accepted for some 
time that stress results in EOP activity in animals and in humans (for reviews see 
Przewlocki, 1993; McCubbin, 1993; Olson & Olson, 1993). According to 
McCubbin (1993), exposure to aversive stimuli which require a coping response 
that is only partially effective results in the release of EOPs. Different laboratory 
procedures have been used to produce a stress induced release of EOPs, such 
as mental arithmetic (Bandura, Cioffi, Taylor, & Brouillard, 1989), exam stress 
(Meyerhoff, Oleshansky, & Mougey, 1988), and exposure to loud noise while 
solving visual spatial problems (Fertig, Peters, Meuller, Kamimori, & Human, 
1992). In summary, stress is an important behavioral variable in drug addiction, 
which is biologically mediated, at least in part, by EOPs. 
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Sensitization of the Dopaminergic Pathways to Drugs and Stress 
Another important dimension of the neurophysiological conceptualization of 
drug addiction is the long-term sensitization of these reinforcement pathways 
(for review see Kalivas & Stewart, 1991; Stewart, 1992; Robinson & Berridge, 
1993). Sensitization may be defined as an increase in response over repeated 
presentations of a stimulus and is thought to be a result of interneuronal 
plasticity (Eikelboom & Stewart, 1982). With repeated administration of a given 
dose of a drug, an organism will demonstrate increases in dopaminergic activity 
. along the reinforcement pathways and increases in behavioral activity. For 
example, with repeated systemic injections of amphetamine or opiates, 
dopamine is released from both cell bodies and terminals and both sensitization 
and stimulus control over the sensitization develops (see Stewart, 1992). 
Likewise, when opiates were injected into the VTA, dopamine is released from 
the cell bodies and terminals and both sensitization and stimulus control 
develops. 
Numerous authors have also demonstrated that stress can sensitize an 
organism to the effects of drugs via EOP activity in the VTA (e.g. Deroche et. al., 
1992; Kalivas, Duffy, Abhold, & Dilts, 1988; Kalivas & Duffy, 1989; Deutch & 
Roth, 1990). For example, Kalivas and Stewart (1991), indicate that both drugs 
and stressors stimulate D1 receptors in the somatodendritic regions of the 
A10/A9 neurons in the VTA, which leads to the development of cross-
sensitization. Furthermore, Kalivas and Abhold (1987) demonstrated that stress 
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led to an increase in enkephalins in the A 10 neuronal region and projections to 
the NA and prefrontal cortex. Over repeated administrations of the footshock 
stressor, this pathway was sensitized to later injections of an enkephalin 
analogue. The sensitization was reversed by injections of naltrexone into the 
VTA. Thus, the cross-sensitization of these pathways to stress and drugs may 
be largely due to a stress induced EOP facilitation of these reinforcement 
pathways. 
A Biobehavioral Model for Stress, Reinforcement, and Drug Abuse 
In summary, drugs which enhance dopaminergic transmission between the 
ventral tegmental area (YTA), nucleus accumbens (NA), amygdala (AMG), and 
other frontal and prefrontal structures along the mesolimbic pathways are 
rewarding and promote approach and appetitive behavior (see Robinson & 
Berridge, 1993). Studies have demonstrated that alcohol, opiates, cocaine, 
amphetamines, and nicotine enhance transmission along these pathways. 
Stress also enhances transmission along these pathways through endogenous 
opioid peptide (EOP) mechanisms, possibly indirectly through an inhibition of 
GABA interneurons which releases dopaminergic neurons from the inhibitory 
action of the GABA interneurons (Kalivas & Stewart, 1991 ). These pathways 
also become sensitized to the effects of drugs such that equivalent doses elicit 
greater behavioral activity and greater release of dopamine from cell bodies. 
Stress also cross-sensitizes these pathways such that an animal which is 
repeatedly stressed demonstrates an enhanced transmission of dopamine when 
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challenged with a drug. In addition, these pathways also come under the control 
of conditioned stimuli in the environment such that these stimuli enhance or 
inhibit the sensitization to the drug (Stewart, 1992). 
We propose that environmental stress initiates EOP activity which partially 
activates the dopaminergic reinforcement pathways, and in a manner similar to 
the effect of opiates on the ICSS threshold, increases the reinforcement value 
and lowers the threshold for reinforcement for subsequent drug administrations. 
With repeated activation by stress or drugs, these pathways become more 
sensitized to environmental cues, the effect of stress, and the effect of the drug 
on these pathways. Thus, the organism becomes increasingly vulnerable to the 
reinforcing effects of stress and drugs. 
Nicotine and a Biobehavioral Model 
Similar to the drugs mentioned above, the reinforcement of nicotine also 
seems to be biologically related to dopaminergic activity and stress. Several 
articles provide evidence that there is an interaction between the mesolimbic 
dopamine pathways and nicotine (Ksir & Cline, 1987; Calabresi, Lacey & North, 
1989; Imperato, Mulas, & Di Chiara, 1986; Balfour, 1994). Furthermore, lesions 
targeted to deplete dopamine in the NA reduce the rate of nicotine self-
administration in rats (Singer, Wallace, and Hall, 1982). 
The research on nicotine also provides evidence that EOPs are involved in 
nicotine administration. In a review of the neurobiology of smoking, Pomerleau 
and Pomerleau (1984) describe several important neuroregulators of smoking, 
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including dopamine and EOPs. They indicate that these neuroregulators may be 
important in terms of initially increasing arousal and attention and reducing 
negative affect. Other researchers have also noted increases in EOP activity as 
a result of smoking (Fertig, Pomerleau, & Sanders, 1986; Gilbert, Meliska, 
Williams, & Jensen, 1992; Wewers, Tejwani, & Anderson, 1994). In a study on 
the effects of opioid antagonists on smoking behavior, Karras & Kane (1980) 
reported that naloxone reduced the desire to smoke and smoking behavior after 
nicotine deprivation in a work setting. In a laboratory replication, Gorelick, Rose, 
and Jarvik (1989) found that naloxone decreases smoking behavior. However, 
Nemeth-Coslett & Griffiths (1986) indicated that naloxone does not decrease 
smoking in a relaxed, naturalistic environment. 
Similar to other drugs, stress also plays an important role in the use of 
nicotine (for reviews see Pomerleau & Pomerleau, 1990, 1984; Carmody, 1989). 
Smokers are often reported to smoke more or desire to smoke more while under 
stress (Spielberger, 1986; Pomerleau & Pomerleau, 1987). A common 
explanation for the relationship is that smoking reduces stress and negative 
affect (e.g., Carmody, 1989). Some studies support this explanation (Perkins, 
Grobe, Fonte, & Breus, 1992; Gilbert & Spielberger, 1987; Jarvik, Caskey, Rose, 
Herskovic, & Sadeghpour, 1989; Rose, Ananda, & Jarvik, 1983), while others do 
not (e.g., Fleming & Lombardo, 1987; Jarvik, Caskey, Rose, Herskovic, & 
Sadeghpour, 1989). Pomerleau and Pomerleau (1991) indicate that anxiety 
reduction may be only indirectly related to smoking. A recent study by Kassel 
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and Shiffman (1995) suggests that the relationship may be mediated by the 
effects of nicotine on attention. Although the mechanisms by which stress and 
smoking are interrelated have not been fully explained, it seems clear that stress 
is an important variable. 
One method of determining the reinforcement value of a drug is the 
behavioral economics paradigm {for review see Bickel, DeGrandpre, & Higgins, 
1993). Two factors are important in the behavioral economics paradigm. First, 
subjects will work less for a reinforcer as the cost, in terms of the number of 
responses required to earn a reinforcer, increases. Secondly, response rate for 
the consumption of a reinforcer will also vary in relation to the availability of 
competing reinforcers. Thus, one measure of reinforcement value is the extent 
to which a subject will respond for a given reinforcer in the context of a 
concurrent reinforcer. Several recent studies have successfully used this 
paradigm to determine the reinforcement value of nicotine under different 
circumstances {Bickel, DeGrandpre, Hughes, & Higgins, 1991; Epstein, Bulik, 
Perkins, Caggiula, & Rodefer, 1991; Perkins, Epstein, Grobe, & Fonte, 1992; 
DeGrandpre, Bickel, Higgins, & Hughes, 1994). In addition, a recent study in 
our lab using a behavioral economics paradigm to examine the reinforcement 
value of nicotine after inducing stress, relaxation, or a no treatment control 
condition, suggested that stress had the effect of increasing the reinforcement 
value of nicotine (Quevedo & Collins, 1993). 
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The present study used a behavioral economics paradigm to examine the 
relationship between stress and the reinforcement value of nicotine. 
Theoretically, EOPs released after stressful events partially activate the 
dopaminergic pathways and change the reinforcement value of nicotine. 
Specifically, pre-treatment with stress may act to decrease the threshold of 
reinforcement and increase the reinforcement value of a subsequent 
administration of nicotine, just as pre-treatment with opioids decrease the 
threshold and increase the reinforcement value of subsequent administrations of 
ICSS. Based on this theory, naltrexone should prevent the increase in the 
reinforcement value of nicotine after stress, by preventing EOPs from activating 
the dopaminergic pathways and decreasing the threshold for reinforcement. 
The first hypothesis of the present study was that stress would increase the 
reinforcement value of nicotine. Specifically, it was predicted that nicotine would 
be more reinforcing after stress and that participants who received stress and 
placebo would increase their responding for nicotine, relative to the no stress 
and placebo condition. The second hypothesis was that naltrexone would 
prevent stress from increasing the reinforcement value of nicotine and that 
participants would experience this effect as a loss of reinforcement. Thus, it was 
predicted that participants who receive stress and naltrexone would respond 
more for nicotine immediately after experiencing this loss of reinforcement, 




Twenty male volunteers were recruited from patients who had expressed 
interest in smoking cessation groups at the VA hospital in Oklahoma City, 
Oklahoma. These subjects were given information about the research study 
when they called to inquire about smoking cessation groups. Participation in 
this study did not delay any smoking cessation treatment which they received. 
As compensation for their participation, each subject received $100 after 
completing the study. Of these twenty subjects, four quit after the first session 
because of the time committment. Three other subjects quit after reporting side 
effects, such as nausea and dysphoria, from the naltrexone. There were 2 other 
subjects who reported nausea on the evening after taking naltrexone for the first 
time, but these subjects did not drop out of the study. Of the 13 subjects who 
finished the study, 77% were White and 23% were Black. The mean age was 
43.1 with a range of 24 to 53, while the mean education was 13. 7 years with a 
range of 12 to 16. The mean number of cigarettes smoked daily was 27.25 with 
a range of 20 to 47. 
The subjects were selected if they had smoked 16 or more cigarettes 
each day for the last year, and did not use other forms of tobacco (i.e. chewing 
tobacco, pipes, or cigars). To insure that each subject smoked regularly, carbon 
monoxide (CO) levels were at least 10 parts per million. Furthermore, subjects 
were not included if they had received treatment for a psychiatric disorder within 
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the last two years, as evidenced by a review of their medical charts at the VA. 
Subjects were also excluded if they scored more than a 47 on the Trait Anxiety 
form of the State Trait Anxiety Inventory (STAI; Spielberger, Gorsuch, & 
Lushene, 1970) or by scoring 16 or more using the Beck Depression Inventory 
(BDI; Beck, Rush, Shaw, & Emery, 1979). Any subject who was excluded for 
one of these reasons was given information regarding the outpatient mental 
health services provided at the VA. 
The STAI is a 40-item instrument comprised of two subscales which 
include Form Y-1 as a measure of state anxiety and Form Y-2 as a measure of 
trait anxiety. Form Y-2 was used for screening subjects. Scores on this 
subscale range from 20 to 80 with higher scores indicating greater levels of 
anxiety. In a normative sample of undergraduates the mean trait score for 
undergraduate men was 36.35 with a standard deviation of 9.67 (Spielberger et. 
al., 1970). Thus, subjects were excluded if their score of Form Y-2 was greater 
than one standard deviation above the mean. The STAI has proven to be a 
reliable and valid measure of anxiety (Spielberger et al., 1970). 
The BDI is a 21-item instrument used to measure symptoms of depression 
(Beck & Steer, 1987). Scores range from O to 63 with scores greater than 16 
indicative of moderate depression. Thus, subjects were excluded if their score 
on the BDI was equal to or more than 16. The BDI has also demonstrated 
reliability and validity (Beck & Steer, 1987). 
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Carbon monoxide (CO) levels were obtained using a handheld 
Vitalograph CO monitor. As mentioned previously, subjects were excluded if 
their CO level was below 10 p.p.m. This is consistent with research suggesting 
that less than 10 p.p.m. is a normal level for nondependent smokers (Lando et 
al., 1991). 
Subjects were also excluded if naltrexone was contraindicated. This included 
subjects who: (1) were currently using or had used within the last month any 
form of exogenous opioid or tested positive for any other drug on a urine drug 
screen; (2) had a history of opioid abuse; (3) had any history of hepatic disease 
or other liver injury including cirrhosis; or (4) had any evidence of liver 
abnormalities as indicated by their medical records and laboratory blood tests. 
A VA physician reviewed the medical data and prescribed the medication 
before each subject began the experimental manipulations. An experimenter 
randomly assigned subjects to the drug condition (naltrexone vs. placebo) and 
the stress condition (stress vs. no stress). A second experimenter who was blind 
to the drug assignment dispensed the medication to the subjects. Subjects were 
not administered naltrexone more than once within one week to insure the 
elimination of the naltrexone before the next administration. 
Apparatus 
The Concurrent VR Schedules of Reinforcement computer program (Collins 
& Carter, 1991) was used to measure the reinforcement value of nicotine. This 
program utilizes a concurrent VR schedule of reinforcement which is portrayed 
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as two slot machines displayed simultaneously on the computer screen. One 
slot machine is used to earn nickels as reinforcers and the other is used to earn 
cigarette puffs as reinforcers. In this program, there are 9 VR schedules which 
are divided into 3 blocks (Block1 = VR 7, VR 11, VR 15; Block 2 = VR 20, VR 25, 
VR 30; Block 3 = VR 41, VR53, and VR 70). The program automatically 
advances to the next schedule when two reinforcers (any combination of coins 
&/or puffs) are earned. At the end of each block, the program pauses to allow 
the participant to collect the reinforcers earned. 
Procedure 
Each subject initially attended a short screening session, during which he 
were generally informed about the nature and purpose of the study. The risks 
involved with the administration of naltrexone was carefully detailed, after which 
each subject was given an informed consent form to sign. Next, each subject 
completed the screening measures outlined above as well as a questionnaire on 
demographics. The medical data was passed to the physician, and those 
subjects who were approved for the study were scheduled for 4 more 
appointments over the course of two weeks to complete the experiment. 
On each of their next 4 appointments, the subjects were given either 50 m.g. 
of naltrexone or a placebo in a plain bottle and instructed that "the bottle either 
contains naltrexone or an inactive pill." The subjects were then asked to smoke 
a cigarette to equate for deprivation level across subjects. The subjects waited a 
total of 90 minutes to begin the experiment after taking the pill to allow the 
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naltrexone to enter the blood stream and cross the blood-brain barrier. Subjects 
were allowed to leave the lab during this time. However, they were asked to 
leave their cigarettes and were instructed not to eat or drink beverages 
containing caffeine. 
At the end of the 90 minutes, the subjects began the experiment by 
completing the first pre-manipulation measure of state anxiety {STAI). The 
subjects then engaged in the first 5-minute experimental manipulation. For the 
subjects in the stress condition, mental arithmetic was performed for 5 minutes. 
Subjects were informed prior to beginning that they were allotted an extra $2.50 
for their performance during a mental arithmetic session and that $.25 would be 
deducted for each incorrect answer they gave. The mental arithmetic consisted 
of subtracting serial 17's from a four digit number. During the 5 minutes, the 
subjects were repeatedly instructed to answer as quickly and accurately as 
possible, and the subjects were informed whether each answer was correct or 
incorrect. Subjects in the no stress condition simply read magazines for 5 
minutes without any pressure or constraints. 
After the 5-minute manipulation, the participants completed the post 
manipulation measure of state anxiety. After completing the STAI, subjects rated 
their desire to smoke using a simple 10-point scale with O equal to no desire and 
1 O equal to extreme desire and then used the computer program to begin 
earning reinforcers for Block 1. After progressing through 3 schedules of Block 
1, the subjects had 5 minutes to smoke the number of puffs earned and/or collect 
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the spare change earned. This cycle was repeated in Block 2 and 3. The 
amount of time necessary to complete a block depended on how fast the subject 
pushed the lever. A subject normally finished Block 1 iri approximately 25 
minutes, Block 2 in 45 minutes, and Block 3 in 1 hour 20 minutes (see Figure 1 
for timeline of assessment administration). 
Insert Figure 1 here 
After the subjects completed all 4 appointments, they were asked to guess 
which days they received naltrexone. They were also debriefed and 
compensated with $100. 
Design 
A four factor within-subjects design (drug x stress x block x schedule) was 
utilized for the statistical analyses. The four factors included drug (naltrexone vs. 
placebo), stress (stress vs. no stress), block and schedule (each VR schedule). 
In addition, the design was counterbalanced across four treatment orders in a 
Latin square arrangement. The first treatment order consisted of placebo and 
stress on session 1, naltrexone and stress on session 2, placebo and no stress 
on session 3, and naltrexone and no stress on session 4. The second treatment 
order consisted of naltrexone and stress, placebo and stress, naltrexone and no 
stress, and placebo and no stress, respectively. The third treatment order 
consisted of placebo and no stress, naltrexone and no stress, placebo and 
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stress, and naltrexone and stress, while the fourth treatment order was 
naltrexone and no stress, placebo and no stress, naltrexone and stress, and 
placebo and stress, respectively. Each treatment order contained 3 subjects, 
except for the first, which contained 4 subjects. 
Results 
Each subject was asked to guess which days they had received the 
medication. If the subjects were guessing at random, they would be expected to 
guess correctly 50% of the time. The subjects guessed correctly on 52% of the 
sessions, indicating that they were unable to reliably discriminate between the 
naltrexone and placebo. 
Data for two of the fifty-two experimental sessions were missing due to 
experimenter error. In both cases, the research assistant failed to administer the 
experimental manipulation (the mental arithmetic task). This occurred once 
during the naltrexone condition and once during the placebo condition. Various 
methods to estimate the missing data were considered,· such as imputing 
unconditional means or using regression equations. However, according to 
Little and Rubin (1987), these methods are unreliable and often require ad hoc 
adjustments to provide accurate estimates. Instead, they recommend using the 
Expectation-Maximization (EM) algorithm to provide Maximum Likelihood 
estimates which are reliable and do not require ad hoc adjustments. The EM 
algorithm estimates the missing data, estimates the parameters of the data set, 
estimates the missing values again while assuming the new parameters are 
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correct, and continues to iterate until convergence. In this case, an EM 
computer program (EMCOV.EXE; Graham, Hofer, & Mackinnon, 1991) was used 
to estimate the missing data. This was done by holding the other factors (i.e., 
schedule, block, and drug) constant while entering the 13 data points for the no 
stress condition and the 12 data points for the stress condition. The last data 
point for the stress condition was then estimated using the EM algorithm. 
Baseline Data 
Analyses of the pre-experimental data were calculated using the baseline 
measure of expired CO as well as state anxiety (STAI) to check for any baseline 
differences between the experimental factors. A repeated measures ANOVA did 
not reveal any significant differences on level of expired CO for drug, stress, or 
an interaction. There were also no significant differences on state anxiety 
before the experimental session began for drug, stress, or an interaction. Thus, 
no baseline differences in anxiety or amount smoked were found. 
Stress Manipulation 
Analyses of the post-manipulation state anxiety were conducted for each 
block to verify that it was effective and to assess any habituation to the stress 
manipulation. These data are presented in Figure 2. A repeated measures 
ANOVA revealed that the stress manipulation was effective in Block 1. When 
subjects performed the mental arithmetic, they scored significantly higher on the 
STAI, F(1, 12) = 8.23, Q < .05, than when they did not. There were no significant 
main effects for the drug or interaction effects. 
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Insert Figure 2 here 
Analyses of state anxiety in the Block 2 also indicated a significant 
difference for stress. When subjects performed the mental arithmetic, they 
scored significantly greater on the STAI, E(1, 12) = 10.88, Q < .01. There were 
no main effects for drug or interaction effects. 
In Block 3, subjects did not report significantly greater anxiety when 
performing the mental arithmetic. There were also no main effects for drug, or 
interaction effects. Thus, the stress manipulation was effective during Block 1 
and Block 2 and not effective in Block 3. 
Effects on the Reinforcement Value of Nicotine 
The reinforcement value of nicotine was operationally defined as the 
percentage of the total possible lever presses made at each schedule. A 
percentage was used to equate the value across the different VR schedules. 
Otherwise, the reinforcement value would rise simply as a function of the 
increase in the VR requirement. Figure 3 represents the percentage of lever 
presses for each combination of drug and stress at each schedule of 
reinforcement. A repeated measures AN OVA was conducted separately for 
each block. To control for a sphericity bias, the Huyhn-Feldt correction (Huynh & 
Feldt, 1976; SAS Institute, 1988) was used to adjust the significance levels as 
needed. 
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Insert Figure 3 here 
In Block 1, the only significant finding was a main effect for schedule, E 
(2,24) = 6.55, Q < .01. However, in Block 2, the analyses revealed a 
significant schedule by drug by stress interaction, E(2,24) = 3.69, Q < .05. Post-
hoc analyses indicated that the number of lever presses for nicotine by subjects 
receiving the naltrexone and stress combination was significantly greater at the 
first schedule of Block 2 as compared to the placebo and stress combination, 
!(12) = 2.14, Q < .05, the placebo/ no stress combination, !(12) = 2.83, Q < .05, 
and the naltrexone and no stress combination, !(12) = 2.51, Q < .05. In Block 3, 
there were no significant effects for drug, stress, or an interaction. 
Analyses were also conducted to determine if stress alone had the predicted 
impact on the reinforcement value of nicotine as it did in a previous study 
(Collins & Quevedo, 1993). For this analysis, the stress and placebo 
combination was compared with the no stress and placebo combination in each 
block. In Block 1, there were no significant effects at the Q < .05 level, although 
there was a trend for an interaction between schedule and stress (E(2,24) = 
3.03, Q = .06). One-tailed dependent! tests revealed that when subjects 
received the stress manipulation, they worked more for puffs at the VR 11 
schedule, !(12) = 2.06, Q < .05. There were no significant differences at VR 7 or 
VR 15. In Blocks 2 and 3, there were also no significant effects. 
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Effects on Self-Reported Desire and Anxiety 
A measure of desire to smoke was collected immediately after each stress 
manipulation. In Block 1, there were no significant effects for drug, stress, or an 
interaction. This was also true for Block 2 and Block 3,. 
The STAI was administered at the beginning of Blocks 1-3. Thus, the 
instrument served as a measure of affect after subjects smoked at the end of 
Block 1 and Block 2. If the subjects who were given naltrexone were 
experiencing a reduction in the reinforcement value of nicotine, it might be 
expected that these subjects would report greater stress or negative affect 
immediately after smoking. Analyses were conducted on the STAI at Blocks 1-3 
to test this hypothesis. Figure 4 represents STAI data for Block 1, Block 2, and 
Block 3. Analyses indicated a significant three way interaction between Block, 
Drug, and Stress, F(2,24) = 3.60, Q < .05, suggesting that subjects receiving 
naltrexone and stress were experiencing more anxiety at Block 2. Post-hoc one-
tailed ! tests revealed that the naltrexone and stress combination resulted in 
greater anxiety when compared to the placebo and no stress combination, !(12) 
= 2.10, Q < .05, and the naltrexone and no stress combination, !(12) = 1.94, Q < 
.05. There was no significant difference between the naltrexone and stress 
combination and the placebo and stress combination at Block 2. 
Insert Figure 4 here 
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Discussion 
The Effect of Stress on the Reinforcement Value of Smoking 
The results of this study indicated that the stress manipulation was effective 
in Blocks 1 and 2 but not in Block 3. The first hypothesis was that stress would 
result in an increase in the reinforcement value of nicotine which would lead to a 
consistent increase in responding across schedules by participants who 
received the stress and placebo combination as compared to the no stress and 
placebo combination. While there was a trend for participants who received 
stress and placebo to respond more for nicotine in Block 1, overall the results 
did not confirm this hypothesis. 
There are three possible explanations for the absence of an effect for the 
stress and placebo combination. First, stress may not alter the reinforcement 
value of nicotine. However, this seems unlikely given the effect of the 
combination of stress and naltrexone, which will be discussed in the following 
paragraphs. Secondly, the behavioral economics paradigm used in this 
experiment may not be sensitive enough to detect changes in the reinforcement 
value of nicotine due to stress. This is consistent with our previous findings, 
which found only a marginal and inconsistent effect for stress (Quevedo & 
Collins, 1993). Finally, the sample used in this study may not have been large 
enough to detect changes in the reinforcement value of nicotine due to stress 
without the added effect of naltrexone. This explanation seems to be the most 
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likely because the interaction between stress and schedule in Block 1 was very 
close to being significant. 
The Effect of Stress and Naltrexone on the Reinforcement Value of 
Smoking 
The second hypothesis was that naltrexone would prevent stress from 
increasing the reinforcement value of nicotine and that participants would 
experience this as a loss of reinforcement and subsequently would respond 
more for nicotine. The data supported this prediction in Block 2 but not in Block 
1 or 3. 
At first glance, these results seem to be incongruous because the effects of 
stress and naltrexone were not consistent across blocks. However, this pattern 
of results is quite consonant with the underlying biobehavioral model. It is our 
assertion that this pattern of results can be attributed to a loss of reinforcement 
that only occurred when the participants of this study were able to experience, 
concurrently, the effects of naltrexone, stress, and nicotine. 
After smoking at the end of Block 1, the demand for puffs decreased for the 
placebo and stress, placebo and no stress, and naltrexone and no stress 
groups. However, the demand for puffs when subjects received naltrexone and 
stress remained high. At the first schedule of Block 2, they worked significantly 
more for puffs when they received naltrexone and stress as compared to any of 
the other three combinations. Across the three schedules of Block 2, their 
demand drops while demand under the other three combinations increases. 
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This effect in Block 2 can be interpreted as a small extinction burst similar to 
what is observed when a reinforcer is diminished or taken away entirely. 
Participants seemed to have experienced a loss of reinforcement after smoking 
at the end of Block 1 which resulted in a increase in their response for nicotine in 
the subsequent VR schedule relative to the other combinations of drug and 
stress. This effect is probably due to the EOP antagonist properties of 
naltrexone which prevented stress from partially activating the dopaminergic 
pathways and prevented a decrease in the threshold for reinforcement. 
Participants experienced this as a reduction of reinforcement. As a result, they 
may have experienced more frustration and anxiety as indicated by their STAI 
scores immediately after smoking prior to Block 2 (see Figure 4). 
The observation that this loss of reinforcement only occurred during Block 2 
is important. Block 2 differs from Block 1 in that subjects did not have the 
opportunity to smoke just prior to beginning the schedules in Block 1. Thus, 
there was no opportunity for subjects in the naltrexone and stress combination to 
experience a loss of reinforcement in Block 1. The absence of a significant 
interaction in Block 1 supports the interpretation that subjects experienced a loss 
of reinforcement only after having a combination of stress, naltrexone, and 
nicotine. 
Another important finding is that naltrexone without stress did not seem to 
have an effect on the reinforcement value of nicotine by itself, which would have 
been expected if naltrexone has a general suppressing effect on the 
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dopaminergic reinforcement pathways. Again, the effect of naltrexone seems to 
be specific to the combination of stress and smoking. Rather than a general 
effect, it seems to specifically prevent EOPs from activating these pathways. 
Nicotine receptors along these pathways would not be blocked and therefore it is 
not surprising that nicotine is still reinforcing. However, since smoking also 
produces increases in EOP activity (Pomerleau & Pomerleau, 1984), naltrexone 
might be expected to have a small effect by preventing this activity from 
stimulating the reinforcement pathways. Previous studies have shown that opioid 
antagonists may have a small effect on smoking (e.g., Gorelick et. al., 1989). It is 
possible that with more subjects or a self-report measure of the initial stimulatory 
and rewarding effects of nicotine, a small effect would have emerged. 
Do the Findings Support the Underlying Biobehavioral Model? 
The failure of the behavioral economics paradigm to demonstrate an effect 
for stress without naltrexone on the reinforcement value of nicotine was 
disappointing. It may be difficult to behaviorally detect changes in the 
reinforcement value of nicotine unless naltrexone is used. However, given the 
difficulty in detecting changes with the present paradigm, it was very 
encouraging to find an effect that was quite strong when stress, naltrexone, and 
nicotine were presented concurrently in Block 2. This pattern of data is 
consistent with a biobehavioral model in which stress, via EOPs, partially 
activates the dopaminergic reinforcement pathways and lowers the threshold for 
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reinforcement of a subsequent dose of nicotine, precipitating an increase in the 
reinforcement value of nicotine. 
Future studies need to explore the effect of naltrexone and stress on the 
subjective experience of reward and self-reported affect. By including a 
measure of self-reported reward, future studies will be able to determine if stress 
does in fact increase the experience of reinforcement after smoking. These 
studies would also be able to test for the effects of naltrexone on self-reported 
reward obtained from smoking. Other researchers have found that naltrexone 
reduces certain self-reported rewarding properties of alcohol, especially the 
stimulatory effects on the ascending arm of the blood alcohol curve (Swift et. al., 
1994). Smokers also report an initial stimulatory effect from smoking (e.g., 
Pomerleau & Pomerleau, 1984), and this effect may also be attenuated by 
naltrexone. 
Future research should also continue to focus on neurophysiological 
components of nicotine addiction. For example, it has been well documented 
that EOP activity and dopaminergic activity are induced by smoking. 
Researchers have also demonstrated that smoking increases attention and that 
this increase in attention may be important in terms of affective regulation (Acri, 
1994; Kassel & Shiffman, 1995). Interestingly, arousal in the form of neural 
activity along the mesolimbic pathways increases attention and increases in 
attention also correspond with increases in reinforcement and reward. Thus, 
there is a great deal of overlap among attention, affect, and reinforcement, and 
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more precise experimentation that includes psychophysiological assessment 
should lead to a model that accurately describes these pharmacological and 
behavioral processes as they relate to drug addiction. 
Several problems with this study need to be addressed. These findings are 
based on a small number of subjects, and it is possible that the results are 
spurious, rather than representing a pattern that is consistent with the 
biobehavioral model reviewed previously. Furthermore, the generalizability of 
these results were limited because of the exclusion of women, the low number of 
subjects, and a subject pool that was limited to veterans without any comorbid 
substance use or psychiatric problems. Future studies need to replicate these 
results with women as well as with populations other than veterans. 
An Integrative Model of Stress, Arousal, Attention, and Reinforcement 
In summary, drugs which enhance dopaminergic transmission between the 
VTA, NA, Amygdala and.other frontal and prefrontal structures along the 
mesolimbic pathways are rewarding and promote approach and appetitive 
behavior. Stress may also enhance transmission along these pathways through 
EOP mechanisms, possibly by inhibiting GABA interneurons which release 
dopaminergic neurons from the inhibitory action of the GABA interneurons. 
These pathways also become sensitized to the effects of drugs and stress such 
that equivalent doses elicit greater behavioral activity and greater release of 
dopamine from cell bodies. Thus, stress also cross-sensitizes these pathways 
such that an animal which is repeatedly stressed demonstrates an enhanced 
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transmission of dopamine when challenged with a drug. In addition, these 
pathways also come under the control of conditioned stimuli in the environment 
such that these stimuli enhance or inhibit the sensitization to the drug. 
The neurophysiological pathways involved in affect, arousal, and attention 
overlap with the pathways involved in drug reinforcement. These pathways have 
also been studied extensively. Lang and associates (1993) have demonstrated 
on numerous occasions that the acoustic startle response (ASR) is influenced by 
ongoing affective and attentional states. In their paradigm, they measure the 
response of the obicularis muscle to acoustic startle probes. They have found 
that foreground stimuli with negative valence enhances the startle response. 
For example, exposure to shock or the threat of shock enhances the startle 
reflex (Greenwald, Bradley, Cuthbert, & Lang, 1990). In addition, picture stimuli, 
films and emotional imagery have all been found to modulate the ASR with the 
positive valence stimuli inhibiting and the negative valence stimuli enhancing the 
ASR. When the ASR is measured early (within 800-1000 m.s.), attentional 
modulation appears to be the dominating factor. Later in the viewing period, 
emotional modulation appears to be the dominating factor. Furthermore, while 
the startle response itself will habituate, the emotional modulation does not, and 
as arousal increases, the strength of the inhibition or enhancement of the ASR 
also increases. 
Another important aspect of the emotional modulation of the ASR is that it 
has a demonstrable pathway. Davis (1992; Davis, Hitchcock, & Rosen, 1992) 
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has demonstrated that the obligatory pathway for the startle reflex involves the 
ear, the cochlear nucleus, reticularis pontis caudalis (RPC), and spine. The 
emotional modulation of this reflex by visual stimuli has been attributed to input 
from the retina and the lateral geniculate to the perirhinal cortex and then to the 
lateral and basolateral nuclei of the amygdala. The central nucleus of the 
amygdala connects to the obligatory circuit via monosynaptic projections to the 
RPC where it modulates the obligatory response. LeDoux (1990) has also 
described the importance of the lateral and central nuclei of the amygdala and 
its afferent connections to the sensory thalamus. Cortical structures also 
activate the amygdala when conditioned stimuli are complex. 
In the drug literature, there is ample evidence of an association between 
stress and addiction. In the animal literature on drug reinforcement, stress is 
associated with the sensitization of the reinforcement pathways. In the animal 
literature on startle response, stress produces a long-term sensitization 
(enhancement) of the ASR (Davis, 1989). In addition, one of the major outputs 
of the amygdala during fear is to the VTA. Complex cues seem to gain neural 
access to the amygdala and enhance startle, just as drug related cues gain 
access to the reinforcement pathways. Thus, both startle and drug taking 
behavior involve some of the same neurophysiological structures and processes. 
Specifically, the amygdala serves a prominent role is negative affect and the 
emotional modulation of startle and has projections to the VTA where it may 
influence drug taking behavior. On the other hand, there are also dopaminergic 
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projections from the reinforcement pathways to the amygdala, which may in turn 
influence the emotional modulation of the ASR. Figure 5 summarizes these 
relationships. Because startle response and drug reinforcement share common 
neurophysiological mechanisms, this methodology may prove to be an important 
measure of sensitization to drugs and drug related cues as well as the effect of 
naltrexone on this sensitization. 
Insert Figure 5 here 
A series of experiments by Stewart (1992) demonstrated that activation of 
the VTA by opiates leads to the integration of sensory information and stimulus 
control over the sensitization of these pathways. This exemplifies the potential 
importance of EOPs in the activation of these pathways and the integration of 
sensory information. It also suggests that drugs such as naltrexone may prove 
to be important in the treatment of addictive behavior. ASR methodology would 
be critical in terms of testing these hypotheses. 
To explain the implications of this overlap in terms of cognition, it may be 
helpful to apply a connectionistic learning model which defines itself by the 
desire to integrate neurophysiological properties, such as neuronal plasticity, 
with principles of learning theory (for review see Martindale, 1991; LeDoux, 
1990, 1993). Basically, the dynamics of a neural network are such that learning 
is the result of changes in the strengths of connections between neural 
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elements. The connection strength is increased when either neural elements 
are activated concurrently for a long period of time or for repeated periods of 
time. Another postulate of this theory is that the arousal system has a 
multiplicative effect on the activation of connections, such that it functions to 
increase in a multiplicative fashion the activation of any given "node." This 
increase in activation and arousal also corresponds to an increase in attention 
and reinforcement. Neurophysiologically, this corresponds to the activation of 
the mesotelencephalic pathways. Cognitively, this serves to strengthen 
connections between sensory information about the environmental and the 
pathways themselves via projections to the cortex. 
Thus, activation along the mesolimbic pathways that results from stress or 
from drugs would result in increased arousal, attention, and reinforcement. The 
strength of connections to cortical structures and the amygdala which encode 
sensory and affective information would be enhanced when these structures are 
repeatedly activated concurrently. The sensory and affective cues which gain 
access to these pathways are then able to modulate the activation. Recent 
studies have provided preliminary evidence that stress increases attention as 
does nicotine (Kassel & Shiffman, 1995; Acri, 1994; Steele & Josephs, 1990). 
Implications for Clinical Treatment and the Use of Naltrexone 
Naltrexone has proven to be a safe and effective pharmacological adjunct in 
the treatment of alcoholics and has been reported to reduce craving for alcohol, 
prevent one drink from priming a relapse, and to decrease the rewarding 
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stimulatory effects of alcohol (Volpicelli et al., 1992; O'Malley et al., 1992; Swift 
et al., 1994). 
The action of alcohol on the dopaminergic reinforcement pathways is similar 
to that of nicotine. Alcohol stimulates the reinforcement pathways and this 
appears to be important in terms of its addictive liability (e.g., Littleton & Little, 
1994). Elevated dopamine levels in the VTA and NA promote drinking while pre-
treatment with pharmacological interventions modifies the reinforcing effects of 
alcohol (Samson & Harris, 1992). Furthermore, EOPs seem to play an 
important role in the reinforcing effects of alcohol. Low doses of alcohol induce 
a release of EOPs from the hypothalamus which seems to mediate the 
stimulatory rewarding effects of alcohol. These doses correspond to the typical 
alcohol concentration observed in the ascending arm of the blood alcohol curve 
(BAC) in humans. This observation is also consistent with research by Swift et. 
al. (1994) in which naltrexone attenuated the stimulatory reinforcing effects of 
alcohol during the ascending arm of the BAC. Naltrexone has also been shown 
to prevent the alcohol induced release of dopamine from the NA in rats 
(Benjamin, Grant, & Pohorecky, 1992). 
Thus, nicotine and alcohol are similar in that both stimulate the release of 
EOPs from the hypothalamus which facilitates dopaminergic activity. This 
activity appears to increase the stimulatory and reinforcing aspects of the drug, 
especially at low doses shortly after administration. These effects appear to be 
blocked by naltrexone which further suggests that EOPs serve a critical role. 
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This is also consistent with the findings of the present study in which EOPs were 
prevented from priming these pathways and subjects experienced a subsequent 
loss of reinforcement from nicotine. 
A sizable amount of research has also been devoted to investigating the role 
of stress and negative affect in cigarette smoking and smoking cessation 
treatment (Abrams et. al., 1987; Zelman, Brandon, Jorenby, & Baker, 1992; 
Tiffany & Drobes, 1990; Brandon, 1994) . Stress and negative affect appear to 
significantly increase the risk of relapse after smoking cessation treatment 
(Brandon, Zelman, & Baker, 1987; Coen & Lichtenstein, 1990; Pomerleau, 
Adkins, & Pertschuk, 1978). Stress also seems to potentiate reactivity to 
smoking cues (Niaura et al., 1992). 
The effect of stress on the dopaminergic reinforcement pathways may 
potentiate the risk for relapse. From a clinical perspective, it would be most 
useful to prevent stress from accessing these pathways. Not only may 
naltrexone decrease the stimulatory reinforcement or reward associated with 
alcohol or nicotine induced EOP activity, this present study suggests that 
naltrexone may have an added prophylactic benefit in that it appears to prevent 
stress from activating these pathways which in turn may help to prevent relapse 
after treatment. 
While naltrexone may help to prevent a relapse to smoking as it does with 
alcohol, the potential efficacy of naltrexone in smoking cessation treatment may 
be even greater. As reviewed previously, opiates administered in the VfA result 
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in the sensitization of these pathways as well as conditioned stimulus control 
over the activation of these pathways (e.g. Stewart, 1992), and stress has a 
similar action via EOP activity in this area (Kalivas & Abhold, 1987). The 
present study indicates that naltrexone may interfere with the activation of these 
pathways and subsequent reinforcement of nicotine after stress. This 
phenomenon may have important implications for a potentially useful treatment. 
Repeated activation of sensory and affective cues while blocking the ability of 
these cues to access the reinforcement pathways could potentially desensitize 
these pathways to the effects of stress and environmental cues. In other words, 
repeated presentation of stress and drug-related cues without the activation of 
the reinforcement pathways would decrease the strength of the neural 
connections. Thus, the ability of affective and environmental cues to prime 
subsequent drug-taking behavior would be minimized. 
Future clinical studies should examine the efficacy of combining naltrexone 
with traditional smoking cessation treatment with the idea that naltrexone may 
facilitate smoking cessation by reducing the reinforcement value of nicotine after 
stress. Naltrexone may also help to prevent relapse once cessation is attained. 
In addition, future clinical trials should evaluate the utility of exploiting a 
combination of exposure to affective cues, smoking, and naltrexone and its effect 
on treatment outcome. 
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Screen Pre Math Post Reinforcers Reinforcers Pre Math Post Reinforcers Reinforcers Pre Math Post Reinforcers Reinforcers 
Assessment 
Medical History X 
Lab Work X 
Demographics X 
BDI X 
ST Al (trait) X 
Smoking History X 
ST Al (state) X X X X X X 
Desire to Smoke X X X 
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